检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:闫源渊 邢国强 杨怀成 张缓 YAN Yuanyuan;XING Guoqiang;YANG Huaicheng;ZHANG Huan(Department of Pharmacy,the First Hospital of Weinan,Weinan 714000,Shaanxi,China;Department of Oncology,the First Hospital of Weinan,Weinan 714000,Shaanxi,China;Department of Pharmacy,Xi’an Yanliang District People’s Hospital,Xi’an 710089,Shaanxi,China)
机构地区:[1]渭南市第一医院药剂科,陕西渭南714000 [2]渭南市第一医院肿瘤科,陕西渭南714000 [3]西安市阎良区人民医院药剂科,西安7100890
出 处:《癌症进展》2023年第11期1257-1260,共4页Oncology Progress
摘 要:目的探讨吉非替尼联合吉西他滨+顺铂治疗晚期非小细胞肺癌患者的疗效及安全性。方法依据治疗方案的不同将80例晚期非小细胞肺癌患者分为对照组和观察组,每组40例,对照组患者给予吉西他滨+顺铂治疗,观察组患者给予吉非替尼联合吉西他滨+顺铂治疗。比较两组患者的临床疗效、肿瘤标志物[细胞角质蛋白19片段抗原21-1(CYFRA21-1)、神经元特异性烯醇化酶(NSE)、糖类抗原19-9(CA19-9)]水平及治疗期间不良反应发生情况。结果观察组患者的客观缓解率、疾病控制率分别为70.00%、95.00%,分别高于对照组患者的47.50%、80.00%,差异均有统计学意义(P<0.05)。治疗后,两组患者血清CYFRA21-1、NSE、CA19-9水平均低于本组治疗前,且观察组患者血清CYFRA21-1、NSE、CA19-9水平均低于对照组,差异均有统计学意义(P<0.05)。观察组患者皮疹、腹泻发生率均明显低于对照组,差异均有统计学意义(P<0.01)。两组患者贫血、恶心呕吐、骨髓抑制、转氨酶升高发生率比较,差异均无统计学意义(P>0.05)。结论晚期非小细胞肺癌患者应用吉非替尼联合吉西他滨+顺铂治疗效果显著,能够明显降低肿瘤标志物水平,减少不良反应,有益于患者预后的改善。Objective To investigate the efficacy and safety of gefitinib combined with gemcitabine+cisplatin in the treatment of advanced non-small cell lung cancer.Method A total of 80 patients with advanced non-small cell lung can-cer were divided into control group(n=40,treatment with gemcitabine+cisplatin)and observation group(n=40,treatment with gefitinib combined with gemcitabine+cisplatin)according to different treatment methods.The clinical efficacy,tu-mor markers[cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),neuron specific enolase(NSE),carbohydrate antigen 19-9(CA19-9)]and adverse reactions were compared between the two groups.Result The objective response rate and disease control rate of the observation group were 70.00%and 95.00%,respectively,which were higher than 47.50%and 80.00%of the control group,and the differences were statistically significant(P<0.05).After treatment,the serum levels of CYFRA21-1,NSE,and CA19-9 in the two groups were lower than those before treatment,and the serum levels of CY-FRA21-1,NSE,and CA19-9 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The incidence of rash and diarrhea in the observation group were significantly low-er than those in the control group,and the differences were statistically significant(P<0.01).There were no significant dif-ferences between the two groups in the incidence of anemia,nausea and vomiting,bone marrow suppression,and transam-inase increase(P>0.05).Conclusion Gefitinib combined with gemcitabine+cisplatin is effective in the treatment of ad-vanced non-small cell lung cancer,which can significantly reduce the levels of tumor markers,reduce the occurrence of adverse reactions,and improve the prognosis of patients.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.117